Drug Targeting Organ-Specific Strategies

152 5 Delivery of Drugs and Antisense Oligonunucleotides to the Proximal Tubular Cell
[21] Manil L, Davin JC, Duchenne C, Kubiak C, Foidart J, Couvreur P, Mahieu P, Pharm. Res. 1994,
11, 1160–1165.
[22] Kitamura M, Taylor S, Unwin R, Burton S, Shimizu F, Fine LG, J. Clin. Invest. 1994, 94, 497–505.
[23] Suzuki K, Susaki H, Okuno S, Yamada H, Watanabe HK, Sugiyama Y, J. Pharmacol. Exp. Ther.
1999, 288, 888–897.
[24] Suzuki K, Susaki H, Okuno S, Sugiyama Y, J. Pharmacol. Exp. Ther. 1999, 288, 57–64.
[25] Suzuki K, Ando T, Susaki H, Mimori K, Nakabayashi S, Sugiyama Y, Pharm. Res. 1999, 16,
1026–1034.
[26] Varki A, Glycobiology. 1993, 3, 97–130.
[27] Ashwell G, Harford J, Annu. Rev. Biochem. 1982, 51, 531–554.
[28] Takakura Y, Hashida M, Pharm. Res. 1996, 13, 820–831.
[29] Kato Y, Sugiyama Y, Crit. Rev. Ther. Drug Carrier Syst. 1997, 14, 287–331.
[30] Tsuchiya T, Saito S, J. Biochem (Tokyo) 1984, 96, 1593–1597.
[31] Sweet DH, Pritchard JB, Cell. Biochem. Biophys. 1999, 31, 89–118.
[32] Endou H, Toxicol. Lett. 1998, 102–103, 29–33.
[33] Hediger MA, Rhoads DB, Physiol. Rev. 1994, 74, 993–1026.
[34] Thorens B, Am. J. Physiol. 1996, 270, G541–G553.
[35] Matsumoto I, Kitagaki H, Iida N, Saito Y, Seno N, Carbohydr. Res. 1986, 151, 261–270.
[36] Liu KX, Kato Y, Kino I, Nakamura T, Sugiyama Y, Am. J. Physiol. 1998, 275, E835–E842.
[37] Watanabe Y, Suzuki H, Suzuki K, Ando T, Nakabayashi S, Sugiyama Y, Pharm. Res. 2000, 17,
49–54.
[38] Haas M, De Zeeuw D, van Zanten A, Meijer DKF, Kidney Int. 1993, 43, 949–954.
[39] Franssen EJF, Moolenaar F, De Zeeuw D, Meijer DKF, Adv. Drug Deliv. Rev. 1994, 14, 67–88.
[40] Susaki H, Suzuki K, Ikeda M, Yamada H, Watanabe HK, Chem. Pharm. Bull. (Tokyo) 1994, 42,
2090–2096.
[41] Susaki H, Suzuki K, Ikeda M, Yamada H, Watanabe HK, Chem. Pharm. Bull. (Tokyo) 1998, 46,
1530–1537.
[42] Lee MR, J. Auton. Pharmacol. 1990, 10, s103–s108.
[43] Barthelmebs M, Caillette A, Ehrhardt JD, Velly J, Imbs JL, Kidney Int. 1990, 37, 1414–1422.
[44] Drieman JC, van Kan FJ, Thijssen HH, van Essen H, Smits JF, Struyker-Boudier HA, Br. J. Pharmacol.
1994, 111, 1117–1122.
[45] Minard FN, Grant DS, Cain JC, Jones PH, Kyncl J, Biochem. Pharmacol. 1980, 29, 69–75.
[46] Orlowski M, Mizoguchi H, Wilk S, J. Pharmacol. Exp. Ther. 1980, 212, 167–172.
[47] Drieman JC, Thijssen HH, Struyker-Boudier HA, J. Pharmacol. Exp. Ther. 1990, 252, 1255–1260.
[48] Drieman JC, Thijssen HH, J. Pharmacol. Exp. Ther. 1991, 259, 766–771.
[49] Drieman JC, Thijssen HH, Zeegers HH, Smits JF, Struyker-Boudier HA, Br. J. Pharmacol. 1990,
99, 15–20.
[50] Elfarra AA, Hwang IY, Drug Metab. Dispos. 1993, 21, 841–845.
[51] Casagrande C, Merlo L, Ferrini R, Miragoli G, Semeraro C, J. Cardiovasc. Pharmacol. 1989, 14,
S40–S59.
[52] Hofbauer KG, Sonnenburg C, Stalder R, Criscione L, Kraetz J, Fuhrer W, Habicht E, J. Pharmacol.
Exp. Ther. 1985, 232, 838–844.
[53] Selhub J, Nakamura S, Carone FA, Am. J. Physiol. 1987, 252, F757–F760.
[54] Christensen EI, Birn H, Verroust P, Moestrup SK, Int. Rev. Cytol. 1998, 180, 237–284.
[55] Birn H, Selhub J, Christensen EI, Am. J. Physiol. 1993, 264, C302–C310.
[56] Morshed KM, Ross DM, McMartin KE, J. Nutr. 1997, 127, 1137–1147.
[57] Mathias CJ, Wang S, Waters DJ, Low PS, Green MA, J. Nucl. Med. 1996, 37, 347P–348P.
[58] Turner FB, Andreassi JL, Ferguson J, Titus S, Tse A, Taylor SM, Moran RG, Cancer Res. 1999,
59, 6074–6079.
[59] Wang S, Low PS, J. Control. Release 1998, 53, 39–48.
[60] Leamon CP Low PS, J. Drug Target. 1994, 2, 101–112.
[61] Lee RJ, Low PS, J. Biol. Chem. 1994, 269, 3198–3204.
[62] Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS, Proc. Natl Acad. Sci. USA. 1995, 92,
3318–3322.
[63] Wang S, Luo J, Lantrip DA, Waters DJ, Mathias CJ, Green MA, Fuchs PL, Low PS, Bioconjug.
Chem. 1997, 8, 673–679.
[64] Clifford AJ, Heid MK, Muller HG, Bills ND, J. Nutr. 1990, 120, 1633–1639.
[65] Franssen EJF, Koiter J, Kuipers CAM, Bruins AP, Moolenaar F, De Zeeuw D, Kruizinga WH,
Kellogg RM, Meijer DKF, J. Med. Chem. 1992, 35, 1246–1259.